Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

83.40
+3.924.93%
Volume:504.13K
Turnover:42.10M
Market Cap:6.81B
PE:-22.60
High:86.06
Open:80.20
Low:80.20
Close:79.48
52wk High:103.00
52wk Low:19.45
Shares:81.64M
Float Shares:54.63M
Volume Ratio:1.42
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6900
EPS(LYR):-3.6900
ROE:-25.78%
ROA:-15.87%
PB:4.31
PE(LYR):-22.60

Loading ...

Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029

TIPRANKS
·
Feb 27

Assessing Kymera Therapeutics (KYMR) Valuation After Equity Offering Losses And Leadership Change

Simply Wall St.
·
Feb 27

Stock Track | Kymera Therapeutics Soars 5.04% Intraday as Analysts Maintain Bullish Ratings Despite Q4 Miss

Stock Track
·
Feb 27

Kymera Therapeutics price target lowered to $123 from $127 at Morgan Stanley

TIPRANKS
·
Feb 27

Kymera Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Feb 27

Kymera Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 27

Kymera Therapeutics Publishes Corporate Presentation on Oral Degrader Medicines for Immunology

Reuters
·
Feb 26

Kymera Therapeutics Inc - 31.39 Mln Shares of Common Stock Offered by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Feb 26

Kymera Therapeutics Inc - Entered Sales Agreement With TD Securities for Common Stock - SEC Filing

THOMSON REUTERS
·
Feb 26

Stock Track | Kymera Therapeutics Plunges 7.37% in Pre-Market After Q4 Earnings Miss Estimates

Stock Track
·
Feb 26

Kymera Q4 revenue misses expectations, net loss widens

Reuters
·
Feb 26

Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Net Loss $0.97 a Share, vs. FactSet Est of $0.78 Loss

MT Newswires Live
·
Feb 26

Kymera Therapeutics reports Q4 EPS (97c), consensus (79c)

TIPRANKS
·
Feb 26

Kymera Q4 net loss widens to USD 87.0 million +23%

Reuters
·
Feb 26

Kymera Therapeutics Q4 EPS $(0.97) Misses $(0.78) Estimate, Sales $2.871M Miss $14.798M Estimate. Cash And Equivalents Of $1.6B

Benzinga
·
Feb 26

BRIEF-Kymera Therapeutics Q4 EPS USD -0.97

Reuters
·
Feb 26

Kymera Therapeutics Inc: Well-Capitalized With $1.6 Bln in Cash as of Dec 31, 2025, and Runway Into 2029

THOMSON REUTERS
·
Feb 26

Kymera Therapeutics Q4 Operating Expenses USD 100.766 Million

THOMSON REUTERS
·
Feb 26

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

GlobeNewswire
·
Feb 26

U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite

Reuters
·
Feb 26